Analyst Reco. The Chemours Company

Equities

CC

US1638511089

Market Closed - Nyse Other stock markets 04:00:01 2024-05-09 pm EDT			5-day change	1st Jan Change
28.43 ^USD	+3.38%		+8.72%	-9.86%

May. 06	Hudson Technologies Signs Licensing Agreement With Chemours	MT
May. 06	Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hudson Technologies Signs Licensing Agreement With Chemours	May. 06	MT
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline	May. 06	MT
BMO Capital Upgrades Chemours to Outperform From Underperform, Raises Price Target to $34 From $19	Apr. 09	MT
UBS Adjusts Chemours Price Target to $28 From $21, Maintains Neutral Rating	Apr. 02	MT
UBS Downgrades Chemours to Neutral From Buy, Cuts Price Target to $21 From $37	Mar. 05	MT
BMO Capital Downgrades Chemours to Underperform From Outperform, Adjusts Price Target to $19 From $45	Mar. 01	MT
RBC Upgrades Chemours to Outperform From Sector Perform, Lifts Price Target to $40 From $28 on Titanium Technologies Recovery, Thermal & Specialized Solutions Strength	Dec. 01	MT
Goldman Sachs Adjusts Chemours' Price Target to $30 From $35, Maintains Neutral Rating	23-10-31	MT
BMO Capital Adjusts Chemours' PT to $39 From $45, Keeps Outperform Rating	23-10-30	MT
Morgan Stanley Cuts Price Target on Chemours to $28 From $33, Maintains Equal-Weight Rating	23-10-30	MT
Barclays Cuts Price Target on Chemours to $28 From $31, Maintains Equal-Weight Rating	23-10-30	MT
RBC Cuts Price Target on Chemours to $28 From $30, Keeps Sector Perform Rating	23-10-30	MT
UBS Cuts Chemours Price Target to $37 From $41, Maintains Buy Rating	23-10-27	MT
RBC Cuts Price Target on Chemours to $30 From $40, Keeps Sector Perform Rating	23-10-23	MT
BofA Securities Adjusts Price Target on Chemours to $32 From $39, Maintains Neutral Rating	23-10-18	MT
UBS Cuts Chemours Price Target to $41 From $47, Maintains Buy Rating	23-10-09	MT
Barclays Adjusts Price Target on Chemours to $31 From $40, Keeps Equalweight Rating	23-10-04	MT
BMO Capital Adjusts Price Target on Chemours to $53 From $64, Maintains Outperform Rating	23-08-02	MT
RBC Boosts Price Target on Chemours to $40 From $37, Maintains Sector Perform Rating	23-07-31	MT
UBS Adjusts Chemours Price Target to $47 From $43, Maintains Buy Rating	23-07-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. The Chemours Company

Equities

CC

US1638511089

Analyst Reco.

Filters